Ganciclovir Treatment of Congenital Cytomegalovirus Infection: A report of two cases
- 1 January 1993
- journal article
- case report
- Published by Taylor & Francis in Scandinavian Journal of Infectious Diseases
- Vol. 25 (3) , 385-388
- https://doi.org/10.3109/00365549309008515
Abstract
Ganciclovir has been shown to be effective against cytomegalovirus (CMV) in vitro, but its role in the treatment of congenital cytomegalovirus infection is unknown. We describe its use in the management of two cases of congenital CMV infections. The drug was well tolerated and virus shedding in the urine was eliminated, though hepatosplenomegaly and neurodevelopmental delay persisted in both cases.Keywords
This publication has 6 references indexed in Scilit:
- GANCICLOVIR—A REVIEW OF PHARMACOLOGY, THERAPEUTIC EFFICACY AND POTENTIAL USE FOR TREATMENT OF CONGENITAL CYTOMEGALOVIRUS INFECTIONSJournal of Clinical Pharmacy & Therapeutics, 1989
- Human pharmacokinetics of the antiviral drug DHPGClinical Pharmacology & Therapeutics, 1986
- Activity of 9-(1,3-dihydroxy-2-propoxymethyl)guanine compared with that of acyclovir against human, monkey, and rodent cytomegalovirusesAntimicrobial Agents and Chemotherapy, 1985
- Epidemiology of Cytomegaloviral Infections: Recommendations for Prevention and ControlClinical Infectious Diseases, 1985
- Congenital and postnatally acquired cytomegalovirus infections: Long-term follow-upThe Journal of Pediatrics, 1984
- Effect of 9-(1,3-dihydroxy-2-propoxymethyl)guanine on human cytomegalovirus replication in vitroAntimicrobial Agents and Chemotherapy, 1983